INT90362

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2000
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.88
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoskeletal protein binding (SDC1) small molecule metabolic process (SDC1) extracellular region (SDC1)
plasma membrane (SDC1) protein complex (SDC1) lipid metabolic process (SDC1)
Anatomy Link Frequency
plasma cells 2
SDC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Multiple sclerosis 40 99.40 Very High Very High Very High
Inflammation 29 96.32 Very High Very High Very High
imagery 19 95.00 High High
metalloproteinase 26 88.48 High High
intrathecal 14 88.32 High High
Chronic pancreatitis 3 78.72 Quite High
Central nervous system 13 54.76 Quite High
Inflammatory response 2 35.96 Quite Low
chemokine 3 5.00 Very Low Very Low Very Low
Migraine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Demyelinating Disease 45 99.40 Very High Very High Very High
Cancer 50 98.90 Very High Very High Very High
Malignant Neoplastic Disease 7 98.36 Very High Very High Very High
Recurrence 7 97.60 Very High Very High Very High
INFLAMMATION 24 96.32 Very High Very High Very High
Disease 20 95.80 Very High Very High Very High
Adhesions 2 94.96 High High
Encephalitis 6 92.24 High High
Skin Cancer 47 90.68 High High
Metastasis 10 83.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Decreased expression of syndecan-1 has been observed in some gastrointestinal malignancies, and it is thought that high levels of syndecan-1 correlate with the maintenance of epithelial morphology and inhibition of invasiveness.
Negative_regulation (Decreased) of Gene_expression (expression) of syndecan-1
1) Confidence 0.59 Published 2000 Journal Int. J. Cancer Section Abstract Doc Link 10962434 Disease Relevance 0.48 Pain Relevance 0.08
Natalizumab, a recently re-approved drug for MS treatment, has been shown to reduce the numbers of CD19+ B cells and CD138+ plasma cells within the CSF [32] which correlated with the reduction of relapse rates as well as of the inflammatory disease activity on MRI.
Negative_regulation (reduce) of Gene_expression (plasma cells) of CD138 in plasma cells associated with multiple sclerosis, inflammation, disease, imagery and recurrence
2) Confidence 0.29 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2438478 Disease Relevance 0.96 Pain Relevance 0.51
In our case tumor cell showed loss of E-cadherin and beta-catenin while syndecan-1 expression was reduced and confined on small group of detached malignant cell.
Negative_regulation (reduced) of Gene_expression (expression) of syndecan-1 associated with malignant neoplastic disease and cancer
3) Confidence 0.01 Published 2011 Journal Diagn Pathol Section Body Doc Link PMC3024921 Disease Relevance 1.43 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox